- Home
- AMLX vs DSL Comparison
AMLX vs DSL Comparison
Compare AMLX & DSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMLX | DSL |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AMLX | DSL |
|---|---|---|
| Price | $18.08 | $10.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $21.56 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 459.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.95% |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $7.48 | $10.49 |
| 52 Week High | $19.15 | $12.67 |
Technical Indicators
Market Signals| Indicator | AMLX | DSL |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 56.78 |
| Support Level | $12.17 | $10.91 |
| Resistance Level | $18.61 | $11.13 |
| Average True Range (ATR) | 1.04 | 0.09 |
| MACD | 0.33 | 0.02 |
| Stochastic Oscillator | 83.43 | 79.64 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.